Ux-Gip001
Temporal Lobe Epilepsy
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Temporal Lobe Epilepsy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nrtx-1001 Neurona Therapeutics | Phase 3 | BB |
NALUZOTAN National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | CCC |
Ferumoxytol University of Alberta | Phase 2 | CCC |
aav9-hsyn1-migrik2 UniQure Biopharma B.V. | Phase 1/2 | CCC |
Florbetaben University of Minnesota | D |
Same molecule, other indications
Ux-Gip001 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →